Ma­gen­ta's R&D head hits the ex­it just weeks af­ter read­ing out mid-stage da­ta for lead ther­a­py, eye­ing clin­ic for an­oth­er

Cam­bridge, MA-based Ma­gen­ta Ther­a­peu­tics has had a most­ly qui­et few years as it steers its stem cell trans­plant hope­fuls through ear­ly-stage hu­man tri­als. For the past three years, that ear­ly clin­i­cal work was head­ed up by Pfiz­er vet­er­an John Davis — but now, Davis is tak­ing off right as the biotech’s lead drug preps for a late-stage test.

Davis, Ma­gen­ta’s CMO and head of R&D, will leave the com­pa­ny as a full-time em­ploy­ee no lat­er than Ju­ly 30 for “fam­i­ly rea­sons,” leav­ing the biotech on the hunt for its next clin­i­cal lead, ac­cord­ing to an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER